Print Clear

Commonwealth of Massachusetts
MassHealth Drug Utilization Review Program
P.O. Box 2586, Worcester, MA 01613-2586
Fax: 1-877-208-7428 **Phone:** 1-800-745-7318

Benign Prostatic Hyperplasia (BPH) Agents Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at **www.mass.gov/druglist**.

Member information

Last name _____ First name _____ MI _____

MassHealth member ID # _____ Date of birth _____

Gender (Check one.) ☐ F ☐ M Member's place of residence ☐ home ☐ nursing facility

Medication information

BPH medication requested

☐ Cardura XL (doxazosin extended-release)
☐ Cialis (tadalafil 5 mg)
☐ dutasteride
☐ dutasteride/tamsulosin
☐ finasteride 5 mg
☐ Rapaflo (silodosin)

Indication (Please check all that apply.)

☐ BPH
☐ Enlarged prostate
☐ Lower urinary tract symptoms
☐ S/P transurethral resection of the prostate (TURP)
☐ Other _____

Please note: MassHealth does not pay for any drug when used for the treatment of male or female sexual dysfunction, cosmetic purposes, or for hair growth as described in 130 CMR 406.413(B): Drug Exclusions.
Dose, frequency, and duration of medication requested _____

Section I. Please complete for Rapaflo requests.

1. Has the member had a trial with tamsulosin?
   ☐ Yes.
   ☐ No. Please provide clinical rationale for not using tamsulosin.
   _____
2. Has the member had a trial with alfuzosin?
   ☐ Yes.
   ☐ No. Please provide clinical rationale for not using alfuzosin.
   _____

Section II. Please complete for dutasteride/tamsulosin requests.

1. Has the member had a trial with an alpha-1 blocker (alfuzosin, doxazosin, tamsulosin, or terazosin)?
   - ☐ Yes. Drug name _____
   - ☐ No. Please provide clinical rationale for not using an alpha-1 blocker (alfuzosin, doxazosin, tamsulosin, or terazosin).

     _____
2. Has the member had a trial with finasteride?
   - ☐ Yes. Dates/Duration of use _____
   - ☐ No. Please provide clinical rationale for not using finasteride.

     _____

Section III. Please complete for Cardura XL requests.

Please attach medical records documenting an inadequate response or adverse reaction to doxazosin immediate release. In addition, attach medical records documenting an inadequate response, adverse reaction, or contraindication to tamsulosin.

Section IV. Please complete for Cialis 5 mg requests.

Please attach medical records documenting an inadequate response, adverse reaction, or contraindication to tamsulosin, alfuzosin, Rapaflo (silodosin), and a 5 alpha-reductase inhibitor (i.e., dutasteride, finasteride). In addition, attach medical records documenting an inadequate response, adverse reaction, or contraindication to combination therapy with an alpha-1 blocker and a 5 alpha-reductase inhibitor.

Section V. Please complete for all requests for non-preferred drug products if one or more preferred drug products have been designated for this class of drugs.

If one or more preferred drug products have been designated for this class of drugs, and if you are requesting PA for a non-preferred drug product, please provide medical necessity for prescribing the non-preferred drug product rather than the preferred drug product.

_____

_____

Prescriber information

Last name* _____ First name* _____ MI _____

NPI* _____ Individual MH Provider ID _____

DEA No. _____ Office Contact Name _____

Address _____ City _____ State _____ Zip _____

E-mail address _____

Telephone No.* _____ Fax No.* _____

* *Required*

over

Prescribing provider’s attestation, signature, and date

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider’s signature (Signature and date stamps, or the signature of anyone other than the provider, are not acceptable.)

Signature required _____

Printed name of prescribing provider _____ Date _____